מושגי ליבה
Omitting SLN biopsy in node-negative breast cancers up to 2 cm with negative preoperative axillary ultrasound results is safe and does not significantly impact outcomes.
תקציר
The study explores the safety of omitting sentinel lymph node (SLN) biopsy in node-negative breast cancers up to 2 cm with negative preoperative axillary ultrasound results. Key points include:
SLN biopsy standard for axillary staging in early breast cancer.
Prospective SOUND trial randomized 1405 women to SLN biopsy or no axillary surgery.
Primary outcome: 5-year distant disease-free survival.
Secondary endpoints: cumulative incidence of distant and axillary recurrences, disease-free survival, and overall survival.
Omitting SLN biopsy did not significantly affect outcomes.
Similar 5-year locoregional relapse rates, distant metastases, and overall survival between groups.
No significant differences in adjuvant treatment recommendations.
Study limitations include short-term follow-up and potential differences in outcomes over a longer period.
סטטיסטיקה
87.8% of patients had ER-positive ERBB2-negative disease.
13.7% of patients in the biopsy group had positive axillary nodes.
3.0% deaths in the SLNB group and 2.6% deaths in the no axillary surgery group.
ציטוטים
"The results of this trial support the safety of omitting axillary surgery in older postmenopausal women with ER-positive ERBB2-negative [breast cancer] who met the SOUND eligibility criteria."